ClinicalTrials.gg
Not yet recruitingNCT07500948EPIC-AIRUpdated Oct 5, 2026

Effectiveness of Pollution Monitoring in Clinical Exercise Rehabilitation

An interventional study of Progressive Walking Exercise Programme and Real-time air quality information and guidance in Cardiovascular Disease, Asthma and COPD, sponsored by University of Leicester. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Leicester · Not applicable, Interventional, and Prevention

How we know

Updated Oct 5, 2026First site in United KingdomStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of EPIC-AIR is to evaluate the feasibility and potential effectiveness of integrating real-time air pollution monitoring into cardiac rehabilitation (CR) and pulmonary rehabilitation (PR) programmes via an online platform that delivers both exercise prescription and air pollution guidance. Specific objectives are: (1) to determine whether access to real-time air quality data reduces modelled ambient pollution exposure (PM2.5, PM10 and NO2) during outdoor physical activity in CR/PR patients and healthy volunteers; (2) to assess the feasibility of the trial design, including recruitment, randomisation, retention, adherence and completeness of outcome data; (3) to measure the impact of the intervention on physical activity levels, health-related quality of life and cardiovascular biomarkers; and (4) to inform the design and sample size of a future definitive randomised controlled trial

Read the detailed description

EPIC-AIR is a single-site, stratified, blinded, two-arm randomised controlled feasibility trial conducted at University Hospitals of Leicester NHS Trust. Up to 80 participants comprising cardiac rehabilitation patients, pulmonary rehabilitation patients and healthy volunteers will be recruited. Following a 1-week baseline monitoring period, participants will be stratified by participant group (cardiac rehabilitation, pulmonary rehabilitation or healthy volunteer) and randomised 1:1 within strata using a computer-generated allocation sequence via the Sealed Envelope secure web-based system.

All participants will receive a Fitbit Charge 6 and a 12-week progressive walking programme delivered through the P-STEP platform. Participants allocated to the intervention arm will additionally receive real-time local PM2.5, PM10 and NO2 information and adaptive guidance concerning the timing, location, route or intensity of outdoor activity. Participants in the control arm will use the same platform and receive the same exercise guidance but without air-quality information or pollution-related guidance.

The primary outcomes are three co-primary pollutant-specific measures: weekly time-weighted mean modelled ambient PM2.5, PM10 and NO2 concentrations during moderate-to-vigorous physical activity (MVPA). Time-stamped GPS locations recorded during activity will be linked to wearable-derived activity data and contemporaneous modelled air-quality concentrations. These outcomes represent modelled ambient concentrations encountered during recorded activity rather than directly measured personal inhaled dose.

Weekly pollution exposure during the 12-week intervention will be analysed using repeated-measures mixed-effects models accounting for participant clustering, baseline exposure, study week, randomisation stratum, sex and calendar week. The principal treatment contrast will be the adjusted average intervention-control difference across the 12-week post-allocation period. Multiplicity across the three co-primary pollutants will be controlled using the Holm procedure.

The registered secondary outcome is weekly physical activity derived from wrist-worn accelerometry. Additional clinical, physiological and patient-reported outcomes will be explored. Feasibility outcomes include recruitment, retention, adherence, completeness of outcome data and adverse events. A final follow-up assessment will take place 3 months after completion of the 12-week intervention. No participants had been recruited at the time the registry record was revised.

02

Conditions studied

  • Cardiovascular Disease
  • Asthma
  • COPD
  • Interstitial Lung Disease Due to Systemic Disease
  • Heart Failure
  • Coronary Heart Disease (CHD)

Keywords

  • air pollution
  • cardiac rehabilitation
  • exercise
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

University of Leicester is the lead sponsor of 172 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort A: Patients with long-term conditions Inclusion criteria for Cohort A are: male or female adults aged ≥18 years; clinical diagnosis of one or more of asthma, , interstitial lung disease (ILD), coronary heart disease (CHD), or heart failure (HF), and signed off for exercise rehabilitation by a clinician; ownership of a GPS-enabled smartphone with internet access; ability to walk outdoors for a minimum of 5 minutes without feeling uneasy or unsteady; availability to complete the 1-week baseline period, 12-week intervention and 3-month post-intervention follow-up within the planned study period; willingness and ability to give ; and willingness to wear a Fitbit device for >70% of the study duration.
  • Inclusion criteria for Cohort B are identical to Cohort A, with the exception that participants must have no diagnosis of asthma, COPD, ILD, CHD, or HF.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria for both cohorts are: diagnosis of dementia, learning disability, severe mental health disorders (excluding depression or anxiety), or epilepsy; receiving palliative care; insufficient English language ability to understand study documentation and use the platform; having been advised not to exercise by a healthcare professional within the past 12 months; currently pregnant; presence of chest pain at rest; and marked unsteadiness when standing or walking.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Air Quality Information Provided

    Participants receive the 12-week progressive walking programme through the P-STEP platform together with real-time PM2.5, PM10 and NO2 information and adaptive pollution-related guidance concerning exercise route, timing and/or intensity.

    Other: Progressive Walking Exercise Programme · Behavioral: Real-time air quality information and guidance

  • Active comparator
    Air Quality Information Not Provided

    Participants receive the same 12-week progressive walking programme through the P-STEP platform, with the same exercise guidance and tracking functions, but without air-quality information or pollution-related guidance.

    Other: Progressive Walking Exercise Programme

Interventions

  • OtherProgressive Walking Exercise Programme

    Participants will receive a progressive, personalised walking exercise programme aimed to increase their weekly levels of physical activity over a 12 week study period.

  • BehavioralReal-time air quality information and guidance

    Real-time air quality information and guidance provided by the online platform.

06

What researchers measure

Primary outcomes

  1. Weekly time-weighted mean modelled ambient PM2.5 concentration during moderate-to-vigorous physical activity

    Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient PM2.5 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient PM2.5 concentration for each participant.

    Time frame: 1-week baseline and weekly throughout the 12 week intervention

  2. Weekly time-weighted mean modelled ambient PM10 concentration during moderate-to-vigorous physical activity

    Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient PM10 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient PM10 concentration for each participant.

    Time frame: 1-week baseline and weekly throughout the 12 week intervention

  3. Weekly time-weighted mean modelled ambient NO2 concentration during moderate-to-vigorous physical activity

    Time-stamped GPS/GNSS locations recorded by the P-STEP platform during Fitbit-derived moderate-to-vigorous physical activity (MVPA) will be linked to contemporaneous modelled ambient NO2 concentration estimates. Concentrations will be time-weighted across eligible MVPA periods to derive a weekly mean ambient NO2 concentration for each participant.

    Time frame: 1-week baseline and weekly throughout the 12 week intervention

Secondary outcomes

  1. Weekly physical activity (weekly minutes, measured by wrist-worn accelerometry)

    Mean minutes of moderate to vigorous physical activity measured continuously over the 12-week intervention period using a wrist-worn accelerometer. The comparison will be change from baseline in mean weekly minutes between the air quality information and control arms at 12 weeks.

    Time frame: 1-week baseline and weekly throughout the 12-week intervention

07

Study locations

1 site
  • Glenfield Hospital, University Hospitals of Leicester NHS Trust, Groby Road
    Leicester, Leicestershire LE39QP, United Kingdom
08

References and documents

Publications

  • McCreanor J, Cullinan P, Nieuwenhuijsen MJ, Stewart-Evans J, Malliarou E, Jarup L, Harrington R, Svartengren M, Han IK, Ohman-Strickland P, Chung KF, Zhang J. Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med. 2007 Dec 6;357(23):2348-58. doi: 10.1056/NEJMoa071535. PubMed 18057337 ↗
  • Sinharay R, Gong J, Barratt B, Ohman-Strickland P, Ernst S, Kelly FJ, Zhang JJ, Collins P, Cullinan P, Chung KF. Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, crossover study. Lancet. 2018 Jan 27;391(10118):339-349. doi: 10.1016/S0140-6736(17)32643-0. Epub 2017 Dec 5. PubMed 29221643 ↗
  • Holgate ST. 'Every breath we take: the lifelong impact of air pollution' - a call for action. Clin Med (Lond). 2017 Feb;17(1):8-12. doi: 10.7861/clinmedicine.17-1-8. PubMed 28148571 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared owing to the sensitive nature of the data collected, which includes continuous GPS-linked location tracking and personal physical activity monitoring. Sharing of granular location data at the individual level would risk re-identification of participants despite anonymisation. Aggregate summary data and analysis code will be made available upon reasonable request to the corresponding author following publication.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 5 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start May 2026 → Oct 2026, primary completion Dec 2026 → Mar 2027 and completion Mar 2027 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Oct 2026was May 2026
Primary completionEst.
Mar 31, 2027was Dec 2026
CompletionEst.
Aug 1, 2027was Mar 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United Kingdom
Show site
  • Glenfield Hospital, University Hospitals of Leicester NHS Trust, Groby Road · Leicester, United Kingdom
Oct 5, 2026
Start date
May 2026→Oct 2026
Oct 5, 2026
Primary completion
Dec 31, 2026→Mar 31, 2027
Oct 5, 2026
Study completion
Mar 1, 2027→Aug 1, 2027
Oct 5, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedCohort A: Patients with long-term conditions Inclusion criteria for Cohort A are: male or female adults aged ≥18 years; clinical diagnosis of one or more of asthma, COPD, interstitial lung disease (ILD), coronary heart disease (CHD), or heart failure (HF), and signed off for exercise rehabilitation by a clinician; ownership of a GPS-enabled smartphone with internet access; ability to walk outdoors for a minimum of 5 minutes without feeling uneasy or unsteady; availability to complete the 131-week baseline period, 12-week intervention and 3-month post-intervention follow-up within the recruitment window (February-May 2026)planned study period; willingness and ability to give informed consent; and willingness to wear a Fitbit device for >70% of the study duration.
Oct 5, 2026
Interventions
Added Behavioral: Real-time air quality information and guidance
Oct 5, 2026
Primary outcomes
3 added, 1 removed
What changed in the outcomes
  • AddedWeekly time-weighted mean modelled ambient PM2.5 concentration during moderate-to-vigorous physical activityTime frame: 1-week baseline and weekly throughout the 12 week intervention
  • AddedWeekly time-weighted mean modelled ambient PM10 concentration during moderate-to-vigorous physical activityTime frame: 1-week baseline and weekly throughout the 12 week intervention
  • AddedWeekly time-weighted mean modelled ambient NO2 concentration during moderate-to-vigorous physical activityTime frame: 1-week baseline and weekly throughout the 12 week intervention
  • RemovedAmbient air pollution exposure per minute of physical activity (µg/m³ per minute of moderate-to-vigorous physical activity per week)Time frame: Baseline to 12 weeks
Oct 5, 2026
Secondary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameWeekly physical activity (weekly minutes, measured by wrist-worn accelerometry)Baseline to 12 weeks → 1-week baseline and weekly throughout the 12-week intervention
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    1 site added — first site in United Kingdom
    Show site
    • Glenfield Hospital, University Hospitals of Leicester NHS Trust, Groby Road · Leicester, United Kingdom
    Start date May 2026→Oct 2026
    Primary completion Dec 31, 2026→Mar 31, 2027
    Study completion Mar 1, 2027→Aug 1, 2027
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedCohort A: Patients with long-term conditions Inclusion criteria for Cohort A are: male or female adults aged ≥18 years; clinical diagnosis of one or more of asthma, COPD, interstitial lung disease (ILD), coronary heart disease (CHD), or heart failure (HF), and signed off for exercise rehabilitation by a clinician; ownership of a GPS-enabled smartphone with internet access; ability to walk outdoors for a minimum of 5 minutes without feeling uneasy or unsteady; availability to complete the 131-week baseline period, 12-week intervention and 3-month post-intervention follow-up within the recruitment window (February-May 2026)planned study period; willingness and ability to give informed consent; and willingness to wear a Fitbit device for >70% of the study duration.
    Primary outcomes 3 added, 1 removed
    What changed in the outcomes
    • AddedWeekly time-weighted mean modelled ambient PM2.5 concentration during moderate-to-vigorous physical activityTime frame: 1-week baseline and weekly throughout the 12 week intervention
    • AddedWeekly time-weighted mean modelled ambient PM10 concentration during moderate-to-vigorous physical activityTime frame: 1-week baseline and weekly throughout the 12 week intervention
    • AddedWeekly time-weighted mean modelled ambient NO2 concentration during moderate-to-vigorous physical activityTime frame: 1-week baseline and weekly throughout the 12 week intervention
    • RemovedAmbient air pollution exposure per minute of physical activity (µg/m³ per minute of moderate-to-vigorous physical activity per week)Time frame: Baseline to 12 weeks
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameWeekly physical activity (weekly minutes, measured by wrist-worn accelerometry)Baseline to 12 weeks → 1-week baseline and weekly throughout the 12-week intervention
    Interventions Added Behavioral: Real-time air quality information and guidance
    + 4 other changes: index terms, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07500948
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

James A Donaldson, Ph.D
Contact
jad72@leicester.ac.uk
+447990571690
Andre Ng, Ph.D, MD
principal investigator · University of Leicester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion